12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III discontinued

OncoGenex and partner Teva said they will conduct an international Phase III trial evaluating custirsen plus Jevtana cabazitaxel as second-line therapy in about 630 men with CRPC in lieu of the Phase III SATURN trial. The new trial will evaluate overall survival (OS) and begin next half. The partners said the...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >